Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články
- Klíčová slova
- Alternative pricing approaches, cancer medicines, europe, managed entry agreements, minimum effectiveness criteria, multicriteria decision analyses, payers, tiered pricing approaches, transparent pricing approaches,
- MeSH
- dávkové mechanismy ekonomika MeSH
- ekonomické modely MeSH
- lidé MeSH
- nádory farmakoterapie ekonomika MeSH
- náklady a analýza nákladů MeSH
- náklady na léky trendy MeSH
- patenty jako téma MeSH
- poskytování zdravotní péče ekonomika MeSH
- protinádorové látky ekonomika MeSH
- vyvíjení léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Evropa MeSH
- Názvy látek
- protinádorové látky MeSH
Introduction: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of their healthcare systems.Areas covered: Narrative discussion principally among payers and their advisers regarding potential approaches to the pricing of new cancer medicines.Expert opinion: A number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models. We are likely to see a growth in alternative pricing deliberations in view of ongoing challenges. These include the considerable number of new oncology medicines in development including new gene therapies, new oncology medicines being launched with uncertainty regarding their value, and continued high prices coupled with the extent of confidential discounts for reimbursement. However, balanced against the need for new cancer medicines. This will lead to greater scrutiny over the prices of patent oncology medicines as more standard medicines lose their patent, calls for greater transparency as well as new models including amortization models. We will be monitoring these developments.
College of Pharmacy Ewha Woman's University Seoul South Korea
Data and Knowledge Integration Center for Health Salvador Bahia Brazil
Department for Health Evidence Radboud University Medical Center Nijmegen The Netherlands
Department of Medicine Lagos State University Teaching Hospital Ikeja Lagos Nigeria
Department of Pharmaceutical Affairs Federation of Social Insurances Vienna Austria
Department of Pharmaceutical and Pharmacological Sciences KU Leuven Belgium
Department of Pharmacology College of Pharmacy Hawler Medical University Erbil Iraq
Department of Pharmacy Faculty of Medicine University of Medicine Tirana Albania
Department of Pharmacy Ministry of Health of the Republic of Lithuania Vilnius Lithuania
Division of Biology and Public Health Mokwon University Daejeon Korea
Drug Department Catalan Health Service Catalan Health Service Barcelona Spain
Faculty of Health and Life Sciences Liverpool UK
Faculty of Health Studies Rijeka Croatia
Faculty of Medicine Slovak Medical University in Bratislava Bratislava Slovakia
Faculty of Pharmacy UBT Higher Education Institution Prishtina Kosovo
Health Insurance Institute Ljubljana Slovenia
Independent Consumer Advocate Brunswick Victoria Australia
Independent Researcher Boston MA United States
Institute of Translational Medicine University of Liverpool UK
Istituto Di Ricerche Farmacologiche 'Mario Negri' IRCCS Milan Italy
National Health Care Institute XH Diemen Netherlands
Pharmaceutical Drug Department Azienda Sanitaria Locale of Verona Verona Italy
Public Health Scotland Edinburgh UK
QC Medica Sim Balk Lane York UK
Reviews and Health Technology Assessments Norwegian Institute of Public Health Oslo Norway
School of National and Kapodistrian University of Athens Athens Greece
School of Pharmaceutical Sciences Universiti Sains Malaysia Penang Malaysia
State Agency of Medicines Tartu Estonia
Statistics Department Bruxelles Belgium
Citace poskytuje Crossref.org
